JWM
CRSP icon

Janiczek Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Janiczek Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$17.1K Hold
317
– – ﹤0.01% 584
2024
Q1 		$21.6K Buy
317
+300
+1,765% +$21.5K ﹤0.01% 557
2023
Q4 		$1.06K Hold
17
– – ﹤0.01% 930
2023
Q3 		$772 Hold
17
– – ﹤0.01% 941
2023
Q2 		$955 Hold
17
– – ﹤0.01% 848
2023
Q1 		$856 Hold
17
– – ﹤0.01% 862
2022
Q4 		$844 Hold
17
– – ﹤0.01% 870
2022
Q3 		$1K Hold
17
– – ﹤0.01% 820
2022
Q2 		$1K Hold
17
– – ﹤0.01% 846
2022
Q1 		$1K Hold
17
– – ﹤0.01% 845
2021
Q4 		$1K Buy
+17
New +$1.49K ﹤0.01% 898

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Janiczek Wealth Management's CRSP Position: Q2 2024 in Review

Janiczek Wealth Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2024 at 317 shares worth $17.1K. The position accounts for ﹤0.01% of the portfolio, ranked #584.

Janiczek Wealth Management first reported a position in CRSP in Q4 2021 and has held it in 11 quarters since. The position peaked at $21.6K in Q1 2024. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

  • Janiczek Wealth Management held 317 shares of CRISPR Therapeutics worth $17.1K as of Q2 2024.
  • Janiczek Wealth Management left its CRISPR Therapeutics share count unchanged in Q2 2024.
  • CRISPR Therapeutics made up ﹤0.01% of Janiczek Wealth Management's portfolio in Q2 2024, its #584 holding.
  • Janiczek Wealth Management first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 11 quarters since.
  • Janiczek Wealth Management's CRISPR Therapeutics position peaked at $21.6K in Q1 2024.
  • 449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Janiczek Wealth Management's 13F filing for Q2 2024, filed 25 Jul 2024.